Mutations in tet methylcytosine dioxygenase 2 (TET2) and DNA methyltransferase 3 alpha (DNMT3A) in AML and myelodysplastic syndrome lead to either hypermethylation or hypomethylation of enhancers, thereby affecting the accessibility of specific TFBS. This evidence concerns the gene TET2 and myelodysplastic syndrome.